Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?

A. Tefferi

Research output: Contribution to journal › Letter › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?'. Together they form a unique fingerprint.